Biological aging is the gradual and progressive decline in system integrity that occurs with advancing chronological age, causing morbidity and disability. Measurements of the rate of biological aging are needed to serve as surrogate endpoints in trials of therapies designed to prevent disease by slowing biological aging to extend healthspan. We report a blood DNAmethylation measure that is sensitive to variation in the pace of biological aging among individuals born in the same year. We first modeled longitudinal change in a panel of 18 biomarkers tracking organ-system integrity across 12 years of follow-up in the Dunedin birth cohort. Rates of change across these biomarkers were composited to form a measure of agingrelated decline in system integrity, termed Pace of Aging. We then used elastic-net regression to develop a DNA-methylation predictor of Pace of Aging, called mPoA for (m)ethylation (P)ace (o)f (A)ging. Validation analyses showed mPoA was associated with functional decline in the Dunedin Study, complemented information from other methylation clocks in the Understanding Society Study, was accelerated by early-life adversity in the E-risk Study, and was disrupted by caloric restriction in the CALERIE trial. Findings provide proof-of-principle for mPoA as a singletime-point measure of a person's pace of biological aging. Belsky mPoA 12-30-19
INTRODUCTION
Aging of the global population is producing forecasts of rising burden of disease and disability (Harper, 2014) . Because this burden arises from multiple age-related diseases, treatments for single diseases will not address the burden challenge (Goldman et al., 2013) .
Geroscience research suggests an appealing alternative: treatments to slow aging itself could prevent or delay the multiple diseases that increase with advancing age, perhaps with a single therapeutic approach (Gladyshev, 2016; Kaeberlein, 2013) . Aging can be understood as a gradual and progressive deterioration in biological system integrity (Kirkwood, 2005) . This deterioration is thought to arise from an accumulation of cellular-level changes. These changes, in turn, increase vulnerability to diseases affecting many different organ systems (Kennedy et al., 2014; López-Otín et al., 2013) . Animal studies suggest treatments that slow the accumulation of cellular-level changes can extend healthy lifespan (Campisi et al., 2019; Kaeberlein et al., 2015) . However, human trials of these treatments are challenging because humans live much longer than model animals, making it time-consuming and costly to follow up human trial participants to test treatment effects on healthy lifespan. This challenge will be exacerbated in trials that will give treatments to young or middle-aged adults, with the aim to prevent the decline in system integrity that antedates disease onset by years. Involving young and midlife adults in healthspan-extension trials has been approved for development by the National Advisory Council on Aging (2019 CTAP report to NACA). In midlife trials of anti-aging treatments, traditional endpoints such as disease diagnosis or death are too far in the future to serve as outcomes. Translation of anti-aging treatments to humans could be aided by measures that quantify the pace of deterioration in biological system integrity in human aging. Such measures could be used as surrogate endpoints for healthy lifespan extension (Justice et al., 2016 (Justice et al., , 2018 Moskalev et al., 2016) , even with young-to-midlife adult trial participants. A useful measure should be non-invasive, inexpensive, reliable, and highly sensitive to biological change.
Recent efforts to develop such measures have focused on blood DNA methylation as a biological substrate highly sensitive to changes in chronological age (Horvath and Raj, 2018) .
Methylation-clock algorithms have been developed to identify methylation patterns that Belsky mPoA 12-30-19 5 characterize individuals of different chronological ages. However, a limitation is that individuals born in different years have grown up under different historical conditions (Schaie, 1967) . For example, people born 70 years ago experienced more exposure to childhood diseases, tobacco smoke, airborne lead, and less exposure to antibiotics and other medications, and lower quality nutrition, all of which leave signatures on DNA methylation (Bell et al., 2019) . As a result, the clocks confound methylation patterns arising from early-life exposures to methylation-altering factors with methylation patterns related to biological aging during adulthood. An alternative approach is to study individuals who were all born the same year, and find methylation patterns that differentiate those who have been aging biologically faster or slower than their same-age peers. The current article reports four steps in our work toward developing a blood DNA methylation measure to represent individual variation in the pace of biological aging.
In
Step 1, which we previously reported , we collected a panel of 18 blood chemistry and organ-system function biomarkers at three successive waves of the Dunedin Longitudinal Study of a 1972-73 population-representative one-year birth cohort (N=1037). We used repeated-measures data collected when Study members were aged 26, 32, and 38 years old to quantify rates of biological change. We modelled the rate of change in each biomarker and calculated how each Study member's personal rate-of-change on that biomarker differed from the cohort norm. We then combined the 18 personal rates of change across the panel of biomarkers to compute a composite for each Study member that we called the Pace of Aging. Pace of Aging represents a personal rate of multi-system decline over a dozen years.
Pace of Aging was normally distributed, and showed marked variation among Study members who were all the same chronological age, confirming that individual differences in biological aging do emerge already by age 38, years before chronic disease onset.
Step 2, which we previously reported, we validated the Pace of Aging against known criteria. As compared to other Study members who were the same chronological age but had slower Pace of Aging, Study members with faster Pace of Aging performed more poorly on tests of physical function; showed signs of cognitive decline on a panel of dementia-relevant neuropsychological tests from an early-life baseline; were rated as looking older based on facial photographs; and reported themselves to be in worse health . Subsequently, we reported that faster Pace of Aging is associated with early-life factors important for aging: familial longevity, low childhood social class, and adverse childhood experiences (Belsky et al., 2017a) , and that faster Pace of Aging is associated with older scores on Brain Age, a machine-learning-derived measure of structural MRI differences characteristic of different age groups . Notably, Pace of Aging was not well-correlated with published epigenetic age clocks, which were designed to measure how old a person is biologically rather than how fast they are aging .
In
Step 3, which we report here, we distill the Pace of Aging into a measurement that can be obtained from a single blood sample. Here we focused on blood DNA methylation as an accessible molecular measurement that is sensitive to changes in physiology occurring in multiple organ systems (Birney et al., 2016; Bolund et al., 2017; Chambers et al., 2015; Chu et al., 2017; Hedman Åsa K. et al., 2017; Ma et al., 2019; Mill and Heijmans, 2013; Morris et al., 2017; Wahl et al., 2017) . We used data about the Pace of Aging from age 26 to 38 years in the Dunedin Study along with whole-genome methylation data at age 38 years. Elastic net regression was applied to derive an algorithm that captured DNA methylation patterns linked with variation among individuals in their Pace of Aging. The algorithm is hereafter termed "mPoA".
Step 4, which we report here, we validate the mPoA in 4 ways. First, using the Dunedin Study, we tested if Study member's mPoA measured when they were aged 38 years could predict deficits in physical and cognitive functioning seven years later, when the cohort was aged 45 years. Second, we applied the mPoA algorithm to methylation data from a second, cross-sectional, study of adults to evaluate patterning of mPoA by chronological age and sex and to test correlations of mPoA with self-reported health and proposed measures of biological age, including three epigenetic clocks. Third, we applied the mPoA algorithm to DNA methylation data from a third, longitudinal, study of young people to test if mPoA was accelerated by exposure to poverty and victimization, factors which are known to shorten healthy lifespan. Finally, to ascertain the potential usefulness of mPoA as a measure for trials of anti-aging treatments, we applied the algorithm to DNA methylation data from a randomized trial of caloric restriction, CALERIE . Earlier we reported from this trial that Belsky mPoA 12-30-19 7 the intervention (two years of prescribed 25% caloric restriction) slowed the rate of biological aging as measured by a blood-chemistry biological-age composite measure (Belsky et al., 2017b) . Here, using newly generated methylation data from blood drawn at the CALERIE baseline assessment, we tested if (a) mPoA from blood drawn before caloric restriction could predict the future rate of biological aging of participants during the two-year trial, and (b) if this prediction was modified in participants who underwent caloric restriction, but not among control participants. We report promising results from this four-step research program, while appreciating that additional measurement development will be needed to support applied use of mPoA. for the methylation data from all studies have been described previously Marzi et al., 2018) . (CALERIE data were processed according to the same protocols used for the We conducted analysis of Dunedin, Understanding Society, E-Risk, and CALERIE data using regression models. For E-Risk analysis, which include data on twin siblings, we clustered standard errors at the family level to account for non-independence of data. CALERIE analysis used mixed-effects growth models (Singer and Willett, 2003) following the method in our original analysis of those data (Belsky et al., 2017b) . All analyses included covariate adjustment for sex. In the Understanding Society and CALERIE studies, we also included covariate adjustment for chronological age. (Dunedin and E-Risk are birth-cohort studies and participants are all the same chronological age.) For regression analysis, methylation measures were adjusted for batch effects by regressing the measure on batch controls and predicting residual values.
METHODS

Data Sources
RESULTS
Capturing Pace of Aging in a single blood test
We conducted analysis to develop the mPoA algorithm using data from Dunedin Study for whom age-38 DNA methylation data were available (N=810). We applied elastic-net regression (Zou and Hastie, 2005) using Pace of Aging between ages 26 to 38 years as the criterion. We included all methylation probes that appear on both the Illumina 450k and EPIC arrays as potential predictor variables. We selected this overlapping set of probes for our analysis to facilitate application of the derived algorithm by other research teams using either chip. We fixed the alpha parameter to 0.5, following the approach reported by Horvath . This analysis selected a set of 46 CpG sites ( (Hartshorne and Germine, 2015; Park et al., 2002) .
Study members with faster age-38 mPoA performed more poorly on all age-45 cognitive tests (r=0.14-0.28, p<0.001 for all). Effect-sizes are graphed in the light-blue bars of Figure 1 , Panel A. Figure 1 ).
Evaluating mPoA and other methylation clocks in the Understanding Society study
To test variation in mPoA and to compare it with published methylation measures of biological aging, we conducted analysis using data on N=1,175 participants aged 28-95 years (M=58, SD=15; 42% male) in the UK Understanding Society cohort. In this mixed-age sample, the mean mPoA was 1.03 years of biological aging per each calendar year (SD=0.07).
We first tested if higher mPoA levels, which indicate faster aging, were correlated with older chronological age. Mortality rates increase with advancing chronological age, although there may be some slowing at the oldest ages (Barbi et al., 2018) . This suggests the hypothesis that the rate of aging increases across much of the adult lifespan. Consistent with this hypothesis, Understanding Society participants who were of older chronological age tended to have faster mPoA (r=0.11, [0.06-0.17], Figure 2 Panel A). We also compared mPoA with three methylation measures of biological age: the epigenetic clocks proposed by Horvath, Hannum, and Levine 13 values, following the procedure used by the developers of the clocks. These residuals are referred to in the literature as measures of "epigenetic age acceleration." None of the 46 CpGs included in the mPoA algorithm overlapped with CpGs in these epigenetic clocks. Nevertheless, mPoA was moderately correlated with epigenetic age acceleration measured from the clocks proposed by Hannum (r=0.24) and Levine (r=0.30) . mPoA was less-well correlated with acceleration measured from the Horvath clock (r=0.06). Associations among mPoA and the epigenetic clocks in the Understanding Society sample are shown in Figure 2 Panel B.
Finally, we tested correlations of mPoA with (a) a measure of biological age derived from blood chemistry and blood pressure data, and (b) a measure of self-rated health. We computed biological age from Understanding Society blood chemistry and blood pressure data following the Klemera and Doubal method (KDM) ) and the procedure described by Levine . Victimization was measured from exposure dossiers compiled from interviews with the children's mothers and home-visit assessments conducted when the children were aged 5, 7, 10, and 12 (Fisher et al., 2015) . Supplemental Table 3 . Differences in mPoA across strata of childhood socioeconomic status and victimization are graphed in Figure   3 .
mPoA measured at baseline in the CALERIE randomized trial predicted future rate of aging measured from clinical-biomarker data
The CALERIE Trial is the first randomized trial of long-term caloric restriction in nonobese adult humans. CALERIE randomized N=220 adults on a 2:1 ratio to treatment of 25% caloric restriction (CR-treatment) or control ad-libitum (AL-control, as usual) diet for two years . We previously reported that CALERIE participants who were randomized to CR-treatment experienced a slower rate of biological aging as compared to participants in the AL-control arm based on longitudinal change analysis of clinical-biomarker data from the baseline, 12-month, and 24-month follow-up assessments (Belsky et al., 2017b . We subsequently generated DNA methylation data from blood DNA that was collected at the baseline assessment of the CALERIE trial for a sub-sample (N=68 AL-control participants and 118 CR-treatment participants). We used these methylation data to calculate participants' mPoA values at study baseline. We then tested if baseline mPoA could predict participants' future rate of biological aging as they progressed through the trial.
We first replicated our original analysis within the methylation sub-sample. Results were the same as in the full sample ( Supplemental Table 4 ). Next, we compared mPoA between CRtreatment and AL-control participants. As expected, there was no group difference at baseline 
DISCUSSION
Breakthrough discoveries in the new field of geroscience suggest opportunities to extend healthy lifespan through interventions that slow biological processes of aging (Campisi et al., 2019) . To advance translation of these interventions, measures are needed that can detect changes in a person's rate of biological aging . We previously showed that the rate of biological aging can be measured by tracking change over time in multiple indicators of organ-system integrity .Here, we report data illustrating the potential to streamline measurement of Pace of Aging to an exportable, inexpensive and non-invasive blood test, and thereby ease implementation of Pace of Aging measurement in studies of interventions to slow processes of biological aging.
We conducted machine-learning analysis of the original Pace of Aging measure using elastic-net regression and whole-genome blood DNA methylation data. We trained the algorithm to predict how fast a person was aging. We called the resulting algorithm "mPoA" for "(m)ethylation (P)ace (o)f (A)ging". There were four overall findings:
First, while mPoA was not a perfect proxy of Pace of Aging, it nevertheless captured critical information about Dunedin Study members' healthspan-related characteristics. Across the domains of physical function, cognitive function, and subjective signs of aging, Study members with faster mPoA at age 38 were worse off seven years later at age 45 and, in repeated-measures analysis of change, they showed signs of more rapid decline. Effect-sizes were equal to or greater than those for the 18-biomarker 3-time point measure of Pace of Aging. In sum, mPoA showed promise as an easy-to-implement alternative to Pace of Aging.
Emerging technologies for deep-learning analysis (Zhavoronkov et al., 2019) may improve methylation measurement of Pace of Aging. Alternatively, integration of methylation data with additional molecular datasets (Hasin et al., 2017; Zierer et al., 2015) may be needed to achieve precise measurement of Pace of Aging from a single time-point blood sample.
Second, mPoA analysis of the Understanding Society sample provided proof-of-concept for using mPoA to quantify biological aging. Age differences in mPoA parallel population demographic patterns of mortality risk. In the Understanding Society sample, older adults had faster mPoA as compared to younger ones. This observation is consistent with the welldocumented acceleration of mortality risk with advancing chronological age (Robine, 2011) .
However, it sets mPoA apart from other indices of biological aging, which are not known to register this acceleration (Finch and Crimmins, 2016) . mPoA may therefore provide a novel tool for testing how the rate of aging changes across the life course and whether, as demographic data documenting so-called "mortality plateaus" suggest, processes of aging slow down at the oldest chronological ages (Barbi et al., 2018) .
mPoA is related to but distinct from alternative approaches to quantification of biological aging. In the Understanding Society sample, mPoA was moderately correlated with aging rates measured by the epigenetic clocks proposed by Hannum et al. and Levine et al. (Hannum et al., 2013; as well as KDM Biological Age derived from clinical biomarker data , and with self-rated health.
Consistent with findings for the measured Pace of Aging , mPoA was only weakly correlated with the multi-tissue clock proposed by Horvath and was more strongly correlated with a clinical-biomarker measure of biological age and with self-rated health as compared to the epigenetic clocks.
Third, mPoA is already variable by young adulthood and is accelerated in young people at risk for eventual shortened healthspan. E-Risk young adults who grew up in socioeconomically disadvantaged families or who were exposed to victimization early in life already showed accelerated mPoA by age 18, consistent with epidemiological observations of shorter healthy lifespan for individuals with these exposures (Adler and Rehkopf, 2008; Danese and McEwen, 2012) . We previously found that Dunedin Study members with histories of earlylife adversity showed accelerated Pace of Aging in their 30s (Belsky et al., 2017a) . mPoA analysis of the E-Risk cohort suggests effects may be already manifest at least a decade earlier. mPoA may therefore provide a useful index that can be applied to evaluate prevention programs to buffer at-risk youth against health damaging effects of challenging circumstances.
Fourth, mPoA analysis of the CALERIE trial provided proof-of-concept for using mPoA to quantify biological aging in anti-aging intervention studies. mPoA measures the rate of aging over the recent past. Control-arm participants' baseline mPoA correlated positively with their clinical-biomarker pace of aging over the two years of the trial, consistent with the hypothesis that their rate of aging was not altered. In contrast, there was no relationship between mPoA and clinical-biomarker pace of aging for caloric-restriction-arm participants, consistent with the hypothesis that caloric restriction altered participants' rate of aging. Ultimately, data on mPoA for all CALERIE participants (and participants in other anti-aging trails) at trial baseline and follow-up will be needed to establish utility of mPoA as a surrogate endpoint. In the mean-time, these data establish potential to use mPoA as a pre-treatment covariate in geroprotector trials to boost statistical power (Kahan et al., 2014) or to screen participants for enrollment, e.g. to identify those who are aging more rapidly and may therefore show larger effects of treatment.
We acknowledge limitations. Foremost, mPoA is a first step toward a single-assay crosssectional measurement of Pace of Aging. The relatively modest size of the Dunedin cohort and the lack of other cohorts that have the requisite 3 or more waves of repeated biomarkers to measure the Pace of Aging limited sample size for our machine-learning analysis to develop methylation algorithms. As Pace of Aging is measured in additional cohorts, more refined analysis to develop mPoA-type algorithms will become possible. In addition, our work thus far has not addressed population diversity in biological aging. 
Figure 4. Change in KDM Biological Age over 24-month follow-up by treatment condition and baseline mPoA in the CALERIE Trial.
Fast mPoA is defined as 1 SD above the sample mean. Slow mPoA is defined as 1 SD below the cohort mean. Slopes are predicted values from mixed effects regression including a 3-way interaction between trial condition, time, and continuous mPoA at baseline. The figure shows that in the Ad Libitum (AL) arm of the trial, participants with fast mPoA at baseline experience substantially more change in KDM Biological Age from baseline to follow-up as compared to AL participants with slow mPoA. In contrast, there was little difference between participants with fast as compared to slow mPoA in the Caloric Restriction (CR) arm of the trial. Chair Stands Chair rises were measured as the number of stands a participant completed in 30 seconds from a seated position Jones and Rikli, 2002) .
Grip Strength
Handgrip strength was measured for the dominant hand (elbow held at 90°, upper arm held tight against the trunk) as the maximum value achieved across three trials using a Jamar digital dynamometer (Mathiowetz et al., 1985; Rantanen T et al., 1999) .
Physical Limitations
Physical limitations were measured with the 10-item RAND 36-Item Health Survey 1.0 physical functioning scale (Ware and Sherbourne, 1992) . Participant responses ("limited a lot", "limited a little", "not limited at all") assessed their difficulty with completing various activities, e.g., climbing several flights of stairs, walking more than 1 km, participating in strenuous sports, etc. Scores were reversed to reflect physical limitations so that a high score indicates more limitations.
Decline in Physical Functioning
Tests of balance and grip strength and interviews about physical limitations were completed at both the age-38 and age-45 Dunedin Study assessments. We measured decline across the 7-year measurement interval by subtracting the age-38 test score from the age-45 test score. Cognitive Functioning (N=795 with mPoA data) Cognitive Functioning
The Wechsler Adult Intelligence Scale-IV (WAIS-IV) (Wechsler, 2008) was administered to the participants at age 45 years, yielding the IQ. In addition to full scale IQ, the WAIS-IV measures four specific domains of cognitive function: Processing Speed, Working Memory, Perceptual Reasoning, and Verbal Comprehension. Cognitive Decline IQ is a highly reliable measure of general intellectual functioning that captures overall ability across differentiable cognitive functions. We measured IQ from the individually administered Wechsler Intelligence Scale for Children-Revised (WISC-R; averaged across ages 7, 9, 11, and 13) (Wechsler, 2003) and the Wechsler Adult Intelligence Scale-IV (WAIS-IV; age 45) (Wechsler, 2008) . We measured IQ decline by comparing scores from the WISC-R and the WAIS-IV. Subjective Signs of Aging (N=802 with mPoA data) Self-rated Health Study members rated their health on a scale of 1-5 (poor, fair, good, very good, or excellent). Facial Aging Facial Aging was based on ratings by an independent panel of 8 raters of each participant's facial photograph. Facial Aging was based on two measurements of perceived age. First, Age Range was assessed by an independent panel of 4 raters, who were presented with standardized (non-smiling) facial photographs of participants and were kept blind to their actual age. Raters used a Likert scale to categorize each participant into a 5-year age range (i.e., from 20-24 years old up to 70+ years old) (interrater reliability = .77). Scores for each participant were averaged across all raters. Second, Relative Age was assessed by a different panel of 4 raters, who were told that all photos were of people aged 45 years old. Raters then used a 7-item Likert scale to assign a "relative age" to each participant (1="young looking", 7="old looking") (interrater reliability = .79). The measure of perceived age at 45 years, Facial Age, was derived by standardizing and averaging Age Range and Relative Age scores. Subjective Decline Self-rated Health and Facial Aging were measured at both the age-38 and age-45 assessments. We measured decline in self-rated health as incident fair/poor health reported at the age-45 assessment. We measured acceleration in Facial Aging by computing the difference in Facial Aging Z-scores between the age-45 and age-38 assessments.
Understanding Society is an ongoing panel study of the United Kingdom population (https://www.understandingsociety.ac.uk/). During 2010-12, participants were invited to take part in a nurse's exam involving a blood draw. Of the roughly 20,000 participants who provided clinical data in this exam, methylation data have been generated for just under 1,200. We analyzed data from 1,175 participants with available methylation and blood chemistry data. Documentation of the methylation (University of Essex, n.d.) and blood chemistry (University of Essex, n.d.) data resource is available online (https://www.understandingsociety.ac.uk/sites/default/files/downloads/documentation/healt h/user-guides/7251-UnderstandingSociety-Biomarker-UserGuide-2014.pdf).
Methylation Clocks. We computed the methylation clocks proposed by Horvath, Hannum, and Levine using the methylation data provided by Understanding Society and published algorithms .
Klemera-Doubal method (KDM) Biological Age. We measured KDM Biological age from blood chemistry, systolic blood pressure, and lung-function data using the algorithm proposed by trained in data from the NHANES following the method originally described by Levine and using the dataset compiled by Hastings (Hastings et al., 2019) . We included 8 of Levine's original 10 biomarkers in the algorithm: albumin, alkaline phosphatase (log), blood urea nitrogen, creatinine (log), C-reactive protein (log), HbA1C, systolic blood pressure, and forced expiratory volume in 1 second (FEV1). We omitted total cholesterol because of evidence this biomarker shows different directions of association with aging in younger and older adults (Arbeev et al., 2016) . Cytomegalovirus optical density was not available in the Understanding Society database.
Self-rated Health. Understanding Society participants rated their health as excellent, very-good, good, fair, or poor. We standardized this measure to have Mean=0, Standard Deviation=1 for analysis.
The Environmental Risk Longitudinal Twin Study tracks the development of a birth cohort of 2,232 British participants. The sample was drawn from a larger birth register of twins born in England and Wales in 1994-1995. Full details about the sample are reported elsewhere (Moffitt and E-risk Team, 2002) . Briefly, the E-Risk sample was constructed in 1999-2000, when 1,116 families (93% of those eligible) with same-sex 5-year-old twins participated in home-visit assessments. This sample comprised 56% monozygotic (MZ) and 44% dizygotic (DZ) twin pairs; sex was evenly distributed within zygosity (49% male). Families were recruited to represent the UK population of families with newborns in the 1990s, on the basis of residential location throughout England and Wales and mother's age. Teenaged mothers with twins were overselected to replace high-risk families who were selectively lost to the register through nonresponse. Older mothers having twins via assisted reproduction were under-selected to avoid an excess of well-educated older mothers. The study sample represents the full range of socioeconomic conditions in the UK, as reflected in the families' distribution on a neighborhood-level socioeconomic index (ACORN [A Classification of Residential Neighborhoods], developed by CACI Inc. for commercial use): 25.6% of E-Risk families lived in "wealthy achiever" neighborhoods compared to 25.3% nationwide; 5.3% vs. 11.6% lived in "urban prosperity" neighborhoods; 29.6% vs. 26.9% lived in "comfortably off" neighborhoods; 13.4% vs. 13.9% lived in "moderate means" neighborhoods, and 26.1% vs. 20.7% lived in "hardpressed" neighborhoods. E-Risk underrepresents "urban prosperity" neighborhoods because such households are likely to be childless.
Home-visits assessments took place when participants were aged 5, 7, 10, 12 and, most recently, 18 years, when 93% of the participants took part. At ages 5, 7, 10, and 12 years, assessments were carried out with participants as well as their mothers (or primary caretakers); the home visit at age 18 included interviews only with participants. Each twin was assessed by a different interviewer. These data are supplemented by searches of official records and by questionnaires that are mailed, as developmentally appropriate, to teachers, and co-informants nominated by participants themselves. The Joint South London and Maudsley and the Institute of Psychiatry Research Ethics Committee approved each phase of the study. Parents gave informed consent and twins gave assent between 5-12 years and then informed consent at age 18. Study data may be accessed through agreement with the Study investigators (https://moffittcaspi.trinity.duke.edu/research-topics/erisk).
Childhood Socioeconomic Status (SES) was defined through a standardized composite of parental income, education, and occupation . The three SES indicators were highly correlated (r=0.57-0.67) and loaded significantly onto one factor. The populationwide distribution of the resulting factor was divided in tertiles for analyses.
Childhood Victimization. As previously described , we assessed exposure to six types of childhood victimization between birth to age 12: exposure to domestic violence between the mother and her partner, frequent bullying by peers, physical and sexual harm by an adult, and neglect.
CALERIE. The CALERIE trial is described in detail elsewhere . Briefly, N=220 normal-weight (22.0 ≤ BMI < 28 kg/m 2 ) participants (70% female, 77% white) aged 21-50 years at baseline were randomized to caloric restriction or ad libitum conditions with a 2:1 ratio (n=145 to caloric restriction, n=75 to ad libitum). "Ad libitum" (normal) caloric intake was determined from two consecutive 14-day assessments of total daily energy expenditure using doubly labeled water . Average percent caloric restriction over six-month intervals was retrospectively calculated by the intake-balance method with simultaneous measurements of total daily energy expenditure using doubly labeled water and changes in body composition (Racette et al., 2012; Wong et al., 2014) . Over the course of the trial, participants in the caloric-restriction arm averaged 12% reduction in caloric intake (about half the prescribed reduction). Participants in the ad libitum condition reduced caloric intake by <2% . CALERIE data are available at https://calerie.duke.edu/samples-dataaccess-and-analysis.
Klemera-Doubal method (KDM) Biological Age. KDM Biological age was measured according to the procedure described in our previous article (Belsky et al., 2017) . Briefly, we computed KDM Biological Age from CALERIE blood chemistry and blood pressure data using the algorithm proposed by trained in data from the NHANES following the method originally described by Levine and NHANES data from years matched to the timing of the CALERIE Trial. We included 8 of Levine's original 10 biomarkers in the algorithm: albumin, alkaline phosphatase (log), blood urea nitrogen, creatinine (log), C-reactive protein (log), HbA1C, systolic blood pressure, and total cholesterol. Cytomegalovirus optical density and lung function were not measured in CALERIE. We supplemented the algorithm with data on uric acid and white blood cell count.
Sensitivity analyses.
We tested sensitivity of mPoA to alternative methods of normalizing DNA methylation data. We normalized data using the 'methylumi' and 'minfi' packages and computed correlations between mPoA measures derived from these two datasets. The correlation was r=0.94. The elastic net model selected 46 CpGs to compose the mPoA. One of these CpGs, cg11897887, has been identified as an mQTL (Volkov et al., 2016) . To evaluate sensitivity of results to the exclusion of this SNP, we computed a version of the mPoA excluding this CpG and repeated analysis. This version of the score was correlated with the full mPoA at r=1. Results were the same in analyses with both versions (available from the authors upon request).
Another CpG selected in the elastic net, cg05575921, is located within the gene AHRR, previously identified as a methylation site modified by tobacco exposure and associated with lung cancer and other chronic disease, e.g. (Fasanelli et al., 2015; Reynolds et al., 2015) . We tested sensitivity of results to the exclusion of this probe using the method described above. This version of the score was correlated with the full mPoA at r=0.94. Again, results were the same in analyses with both versions (available from the authors upon request).
Bootstrap repetition analysis to estimate out-of-sample correlation between mPoA and longitudinal Pace of Aging.
The Dunedin Study is the only dataset to include measured 12-year longitudinal Pace of Aging. To estimate the out-of-sample correlation between mPoA and the original Pace of Aging measure, we conducted 90/10 crossfold validation analysis. We randomly selected 90% of the cohort to serve as the "training" sample in which the mPoA algorithm was developed. We used the remaining 10% to form a "test" sample to estimate the correlation between mPoA and Pace of Aging. We repeated this analysis across 100 bootstrap repetitions. In each repetition, we randomly sampled 90% of the cohort to use in the training analysis and reserved the remaining 10% for testing.
The mPoA algorithms developed across the 100 bootstrap repetitions included different sets of CpGs (range of 21-209 CpGs selected, M=54, SD=27 CpGs). However, the resulting Figure 1B and are reported in terms of standard deviation differences in the age-45 outcome associated with a 1 standard deviation increase in mPoA (i.e. effect-sizes are interpretable as Pearson r). All models were adjusted for sex. 
